Sun Pharma Announces Pre-Clinical Data on GL0034, an Experimental NCE to Treat Type 2 Diabetes and Obesity
- Category: Small Molecules
- Published on Wednesday, 24 June 2020 17:27
- Hits: 755
MUMBAI, India I June 24, 2020 I Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries and/or associate companies) today announced an update on the pre-clinical molecule, for which a disclosure was made in the Q1FY20 results press release. The experimental New Chemical Entity (NCE), GL0034 is a long-acting GLP-1R (Glucagon-Like Peptide-1 Receptor) agonist. Such agonists are used to treat patients with type 2 diabetes, including short-acting, intermediate-acting, and long-acting therapies1.
The pre-clinical data for GL0034 was recently presented at the American Diabetes Association (ADA) Virtual 80th Scientific Sessions. GL0034 has been developed internally by Sun Pharma's High Impact Innovations - Sustainable Health Solutions (HISHS) Discovery Team.
Pre-clinical performance of GL0034 was assessed in a highly relevant type 2 diabetes db/db mouse model. The NCE demonstrated significant outcomes on various diabetic parameters evaluated, viz. glucose reduction, decrease in HbA1c (an important marker for clinical efficacy), augmented insulin secretion, lowering of glucagon level and a marked and meaningful reduction in triglyceride levels. All these outcomes with GL0034 were found to be higher or significant to the currently marketed once a week GLP-1R agonists compared in the study.
Yet another important feature in diabetes treatment is weight management. GL0034 induced a larger body weight reduction, 1.9x and 3.8x times higher than the two different standard once a week GLP-1R agonist drugs compared in the study, with similar food consumption.
Dilip Shanghvi, Managing Director, Sun Pharma said, "We are excited by the robust pre-clinical data for GL0034 and believe that it has significant potential. We look forward to validating this data in human clinical trials."
Sun Pharma is planning to initiate Phase-1 clinical trials for GL0034 by Q3FY21.
About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050)
Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 7% of annual revenues in R&D. For further information, please visit www.sunpharma.com<http://www.sunpharma.com> & follow us on Twitter @SunPharma_Live<https://twitter.com/sunpharma_live>.
1. Hinnen, D. Diabetes Spectr. 2017; 30:202-10.
SOURCE: Sun Pharma